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O B J E C T I V E S The objective of the study was to determine whether the extent of left ventricular
scar, measured with delayed hyperenhancement cardiac magnetic resonance (DHE-CMR), predicts
survival in patients with ischemic cardiomyopathy (ICM) and severely reduced left ventricular ejection
fraction (LVEF).
B A C KG ROUND Patients with ICM and reduced LVEF have poor survival. Such patients have a high
myocardial scar burden. CMR is highly accurate in delineation of myocardial scar.
METHOD S We studied 349 patients (76% men) with severe ICM (70% disease in 1 epicardial
coronary, and mean LVEF of 24%) that underwent DHE-CMR (Siemens 1.5-T scanner, Erlangen, Germany),
between 2003 and 2006. Scar (quantiﬁed as percentage of myocardium) was deﬁned on DHE-MR images
as an intensity 2 standard deviations above the viable myocardium. Transmurality score was
semiquantitatively recorded in a 17-segment model as: 0  no scar, 1  1% to 25% scar, 2  26% to
50%, 3  51% to 75%, and 4  75%. The LVEF, demographic data, risk factors, need for cardiac
transplantation (CTx), and all-cause mortality were recorded.
R E S U L T S The mean age and follow-up were 65  11 years and 2.6  1.2 years (median 2.4 years
[1.1, 3.5]), respectively. There were 56 events (51 deaths and 5 CTx). Mean scar percentage and
transmurality score were higher in patients with events versus those without (39  22 vs. 30  20, p 
0.003, and 9.7  5 vs. 7.8  5, p  0.004). On Cox proportional hazard survival analysis, quantiﬁed scar
was greater than the median (30% of total myocardium), and female gender predicted events (relative
risk 1.75 [95% Conﬁdence Interval: 1.02 to 3.03] and relative risk 1.83 [95% Conﬁdence Interval: 1.06 to
3.16], respectively, both p  0.03).
CONC L U S I O N S In patients with ICM and severely reduced LVEF, a greater extent of myocardial
scar, delineated by DHE-CMR is associated with increased mortality or the need for cardiac transplan-
tation, potentially aiding further risk-stratiﬁcation. (J Am Coll Cardiol Img 2009;2:34–44) © 2009 by the
American College of Cardiology Foundation
From the Departments of *Cardiovascular Medicine, †Internal Medicine, and ‡Radiology, Cleveland Clinic, Cleveland, Ohio.
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35eart failure is responsible for approximately
2.6 million annual hospital stays, and there is
a rising incidence that is expected to double in
the next 40 years (1). The most common
ause of systolic heart failure, particularly in developed
ations, is ischemic cardiomyopathy (ICM), resulting
rom significant coronary artery disease (CAD) (2).
atients with ICM and severe systolic left ventricular
LV) dysfunction have a significantly higher mortality,
ompared with the general population, as a result of
See page 45
ultiple factors, including progressive heart failure
nd tachyarrhythmia (3–5). Despite significant ad-
ancements in therapies (revascularization, device
herapy, transplantation medicine, or medical ther-
pies), outcomes in severe heart failure are generally
oor (2). Furthermore, in specific subsets of pa-
ients (e.g., those with severe LV dysfunction), the
otential benefits of revascularization must be
eighed against increased periprocedural risks.
herefore, knowledge of myocardial viability might
e useful in the decision-making process with
egard to such patients.
Delayed hyperenhancement cardiac magnetic reso-
ance (DHE-CMR), after administration of a
adolinium-based contrast agent, has been shown to
dentify areas of myocardial infarction (MI) with a
igh degree of accuracy and reproducibility (6–9).
tudies have clearly demonstrated the role of DHE-
MR in predicting functional recovery after revascu-
arization in patients with ICM (10,11). Furthermore,
ecent data also indicate that infarct size, quantified by
HE-CMR, identifies patients at risk for inducible
entricular tachycardia and mortality, more reliably
han left ventricular ejection fraction (LVEF) (3,12).
In patients with systolic LV dysfunction due to
CM, LVEF has been shown to be a strong
redictor of sudden death (13,14) and might be a
urrogate marker for infarct size. However, it is
nclear whether the amount of MI-related scar
issue further impacts survival in such patients. We
ought to determine whether precise quantification
f infarct (scar) size by DHE-CMR is associated
ith survival in patients with ICM and severe LV
ystolic dysfunction.
E T H O D S
his was an observational study of 349 patients
ith documented ICM (on the basis of 70%tenosis in at least 1 epicardial coronary vessel on cngiography and/or history of MI or coronary
evascularization), who were referred for the assess-
ent of myocardial viability with cardiac magnetic
esonance (CMR) between January 2003 and De-
ember 2006. Patients with standard CMR contra-
ndications—including severe claustrophobia, atrial
brillation, and the presence of pacemakers, defi-
rillators, or aneurysm clips—were not imaged.
lso, no patients were imaged in the immediate
eri-infarct period. Electronic medical records were
ueried to determine clinical and demographic
ariables, at a time temporally closest to the CMR
tudy (within 1 month). Medication use, including
eta-blockers, angiotensin-converting enzyme in-
ibitors (ACE-I) (angiotensin receptor blockers
ncluded in this group), spironolactone, and statins,
ere recorded. The incidence of post-CMR study
oronary revascularization (either percutaneous or
urgical) and placement of implantable
ardioverter defibrillators (ICD)/cardiac
esynchronization therapy (CRT) was also
ecorded. The institution’s angiographic
atabase was queried to assess for presence
nd degree of CAD. All patients had
70% stenosis in 1 epicardial coronary
essel or had a documented history of MI
nd/or previous coronary revascularization
corroborating the diagnosis of ICM).
he institution’s echocardiography data-
ase was similarly queried (data from sur-
ace echocardiogram performed within 1
eek of the CMR study were recorded).
ll patients had to have an LVEF 45%
n initial surface echocardiography, to be
onsidered in the study population. The
nstitution’s cardiac transplantation (CTx)
atabase was queried to ascertain any history of
uch, after the CMR study. All-cause mortality was
scertained by social security death index. We
easured a composite end point of all-cause mor-
ality or CTx in the period after CMR study. This
tudy was approved by the institutional review
oard with a waiver of individual consent.
MR protocol and analysis. The CMR examinations
ere performed on 1.5-T MR scanners (Siemens
edical Solutions, Erlangen, Germany), either So-
ata (for examinations between 2002 and 2005, 40
T/m maximum gradient strength, 200 T/m/s max-
mum slew rate) or Avanto (for examinations in 2006,
5 mT/m maximum gradient strength, 200 T/m/s
aximum slew rate), with electrocardiographic gating.
cout images were acquired initially to identify the
A B B
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36alanced steady-state free precession (bSSFP) images
ere then acquired: echo time  1.6 ms, repetition
ime 3.3 ms, flip angle 70°, and slice thickness
mm (long-axis images) or 8 to 10 mm (contiguous
hort-axis images encompassing the entire LV vol-
me, from apex to base). For short-axis images, the
eld of view varied from 228 to 330 in the x-direction
nd 260 to 330 in the y-direction, and matrix size
aried from 140 to 180 in the x-direction (phase
ncoding direction) and 256 in the y-direction. This
ave a spatial resolution of 1.5 to 2.1 mm (x-direction)
1.1 to 1.4 mm (y-direction). In long-axis images,
he field of view varied from 250 to 320 (x-direction)
nd 280 to 340 (y-direction). Matrix size varied from
20 to 210 in the x-direction (phase encoding direc-
ion) and 256 in the y-direction. This gave a spatial
esolution of 1.5 to 2.1 mm (x-dir)  1.1 to 1.6 mm
y-direction). For patients able to suspend respiration,
reath hold duration was 10 to 15 s, depending on the
eart rate; otherwise, images were acquired with 3
ignal averages. The LV volumes and LVEF were
alculated on the basis of short-axis bSSFP images.
Subsequently, DHE-CMR images were ob-
ained in the same long- and short-axis orientations
s the previously described bSSFP images, approx-
Short-Axis Delayed Hyperenhancement Image, Loaded on
PT Software (Siemens Research), for Scar Analysis
-axis level was segmented (white lines) according to the standard
eart Association 17-segment model. The blue circle represents
on of the normal nulled myocardium and adjacent tissues, for the
f thresholding (as recommended by the developer of the soft-
green and red circles represent delineation of epicardium and
m. The bright red areas within the myocardium represent the
lly detected myocardial scar.mately 20 min after injection of 0.2 mmol/kg of madolinium dimenglumine (Magnevist, Berlex Im-
ging, Wayne, New Jersey), with a phase-sensitive
nversion recovery spoiled gradient echo sequence:
chocardiography time 4 ms, repetition time 8 ms,
ip angle 30°, bandwidth 140 Hz/pixel, 23 k-space
ines acquired every other RR-interval, field of view
varied from 228 to 330 in the x-direction and 260
o 330 in the y-direction), and matrix size (varied
rom 140 to 180 in the x-direction and 256 in the
-direction). This gave a spatial resolution of 1.5 to
.1 mm (x-direction) by 1.1 to 1.4 mm (y-direction).
For DHE-CMR analysis, the images were first
oaded on a custom analysis package (VPT soft-
are, Siemens Medical Solutions), and endocardial
nd epicardial myocardial edges were manually
elineated on the DHE-CMR images. Scar was
efined as having an intensity 2 standard devia-
ions above viable myocardium (identified by a
ser-specified region of interest) (Fig. 1) (15,16).
ny areas that were identified as scar by the
oftware but not deemed to be scar by the user (e.g.,
reas outside of the epicardium that were included
ue to irregular heart borders) were excluded man-
ally by the user. Scar burden was assessed both
uantitatively and qualitatively (by investigators
.H.K., C.M.H., and M.Y.D.): 1) quantity of scar
as automatically determined (as percentage of
otal myocardium; such quantitative scar analysis
as been shown to be highly reproducible in a
revious study from our institution with a bias of
nly 1% both between and within readers on
land-Altman analysis and intraclass correlation
oefficients of 0.84 and 0.88 for interobserver and
ntraobserver agreement, respectively [15]; and 2)
ach study was also semiquantitatively graded, with
standard American Heart Association 17-
egment model (17), on a 5-point scale (segmental
car score), with 0  absence of DHE; 1  DHE
f 1% to 25% of LV segment; 2  DHE extending
o 26% to 50%; 3  DHE extending to 51% to
5%; and 4  DHE extending to 76% to 100% (7).
o further semiquantitatively define the extent/
ransmurality of scar tissue, the following defini-
ions were used (18): 1) transmurality score, defined
s number of segments with a segmental scar score
f 3 or 4; and 2) total scar score, defined as summed
egmental scar scores/patient divided by 17 (which
eflects the damage/patient, with the maximum
ossible score being 4). The CMR analysis was
ompletely blinded from the clinical analysis.
tatistical analysis. Baseline demographic data, risk
actors, and clinical variables are descriptively sum-Figure 1.
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37xpressed as mean  SD. Categorical data are
resented as percentage frequency. Differences be-
ween the groups were compared with the use of the
tudent t test and analysis of variance for continu-
us variables and the chi-square test for categorical
ariables. To verify that the groups were well-
atched according to their baseline characteristics,
e calculated propensity scores with logistic regres-
ion analysis (19,20) with age, gender, diabetes
ellitus, hypertension, medication usage, LVEF,
ost-CMR revascularization, or ICD/CRT as in-
ut variables. Both groups had similar propensity
cores (0.04  0.36 vs. 0.10  0.32, p  0.4),
hich enabled comparison of 2 entire groups in a
tatistically unbiased manner. Further details of
ropensity analysis are shown in the Online Ap-
endix. We measured a composite end point of
ll-cause mortality or CTx in the period after CMR
tudy. Exclusion of 5 CTx cases as an end point did
ot alter the results presented herein. Univariable
nd multivariable survival analysis was performed
Table 1. Demographic Data of the Study Population, on the Ba
Total
(n  349)
G
No
(n
Age, yrs 6
Male 22
Hypertension 11
Diabetes mellitus 8
Documented myocardial infarction 2
History of prior coronary artery bypass grafting 2
Statins 16
Beta-blockers 17
ACE inhibitors 14
Aldosterone 7
LVEF (%) 2
Left ventricular end-diastolic volume (ml) 22
Left ventricular end-systolic volume (ml) 13
Post-CMR coronary revascularization 7
Post-CMR ICD or CRT 8
Values are n (%).
ACE  angiotensin-converting enzyme; CMR  cardiac magnetic resonance
implantable cardioverter-deﬁbrillator; LVEF  left ventricular ejection fraction.
Table 2. DHE-CMR Analysis of the Study Population, on the Bas
Group 1
No Events
(n  293)
Mean scar % on DHE-CMR 30 20
Transmurality score on DHE-CMR 7.8 5
Total scar score on DHE-CMR 2.0 1.1DHE-CMR  delayed hyperenhancement cardiac magnetic resonance.ith Cox-proportional hazards analysis, and risk
atios were generated. For univariable survival anal-
sis, the following variables were tested: age, gen-
er, medications, history of hypertension, diabetes
ellitus, post-CMR revascularization, post-CMR
CD or CRT implantation, LVEF mean, and
oth semiquantitative (total scar score median of
2.3) and quantitative (automatically detected scar
edian of 30%) scar burden. For backward step-
ise multivariable Cox proportional hazards analy-
is, we included only those variables with a p value
f 0.10. For Kaplan-Meier survival analysis, pa-
ients were divided into 4 groups stratified accord-
ng to quartiles of semiquantitative and quantitative
car burden, and between-group differences in sur-
ival were tested by log-rank statistics. Receiver-
perating characteristic curve analysis was per-
ormed to test the association between scar burden
nd survival. Data assembly and basic statistical
omparisons were performed with JMP Software
ersion 6.0.2 (SAS Institute, Cary, North Caro-
f Composite End Points of Survival or Cardiac Transplantation
1
nts
93)
Group 2
Composite Events
(n  56) p Value
11 67 11 0.17
%) 33 (64%) 0.03
%) 17 (30%) 0.30
%) 15 (27%) 0.77
) 6 (11%) 0.49
) 2 (4%) 0.12
%) 24 (43%) 0.06
%) 25 (45%) 0.03
%) 22 (39%) 0.22
%) 13 (23%) 0.70
8 23 7 0.39
100 235 127 0.67
83 141 109 0.48
%) 14 (25%) 0.93
%) 13 (23%) 0.47
T  cardiac resynchronization therapy with biventricular pacemaker; ICD 
f Composite End Points of Survival or Cardiac Transplantation
Group 2
Composite Events
(n  56) p Value
39 22 0.003
9.7 5 0.004
2.5 1.1 0.004sis o
roup
Eve
 2
5
9 (78
0 (38
4 (28
3 (8%
7 (9%
5 (56
6 (60
1 (48
5 (26
4
7
0
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38ina). Advanced statistical analysis and graph gen-
ration was performed with SPSS version 10.0
SPSS Inc., Chicago, Illinois) and Statistica version
.1 (Statsoft, Tulsa, Oklahoma). A p value  0.05
as considered significant.
E S U L T S
atient population. The mean age of the study
opulation (n  349) was 65  11 years, with the
Figure 2. Kaplan-Meier Curves Demonstrating Difference in Out
(A) Kaplan-Meier curves demonstrating difference in outcomes amo
left ventricular myocardium); 0% to 14%  1st quartile, 14.1% to 30
quartile. (B) Difference in outcomes among 4 quartiles of semiquan
quartile, 2.31 to 3.0  3rd quartile, and 3.1  4th quartile. Continajority being Caucasian (86%) and male (76%). In the study, the mean age for men versus women was
imilar (66  11 years vs. 64  12 years, p  0.20).
ver a mean follow up of 2.6  1.2 years (median
.4 years [interquartile range 1.1, 3.5]), there were a
otal of 56 composite events (51 deaths and 5
Txs). The patients were subsequently divided into
groups: group 1 (no events) and group 2 (com-
osite events). Baseline characteristics of the 2
roups are provided in Table 1. The LVEF was
epressed to a similar extent in both groups (75% of
es Among 4 Quartiles
4 quartiles of automatically derived scar (as a percentage of total
2nd quartile, 30.1% to 46%  3rd quartile, and 46%  4th
ive total scar score; 0 to 1.3  1st quartile, 1.31 to 2.3  2nd
on next page.com
ng
% 
titathe study population had an LVEF 30%) along
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39ith a similar frequency of other cardiac risk
actors (Table 1). The frequency of post-CMR-
evascularization and ICD/CRT was also similar
n both groups. In the follow-up period, 30% of
atients that underwent revascularization had an
mprovement in LVEF 35%. In the follow-up
eriod, there was no significant difference in the
ate of ICD discharges between the 2 groups (4%
s. 7%, p  0.26). To ascertain the similarity of
aseline characteristics in 2 groups, we also cal-
ulated propensity scores.
Number of patients at risk of events
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Figure 2. Continued
(C) Difference in outcomes among 4 quartiles of transmurality score
quartile, and 12.0  4th quartile.
Table 3. Cox Proportional Hazard Analysis Demonstrating the A
Univ
Relative R
95% C
Age (yrs) 1.01 (0.99–1
Female gender 1.83 (1.06–3
Diabetes mellitus 0.96 (0.53–1
Hypertension 0.73 (0.41–1
Statins 0.75 (0.44–1
Beta-blockers 0.65 (0.39–1
ACE inhibitor 0.75 (0.44–1
LVEF 0.98 (0.95–1
Post-CMR revascularization 0.98 (0.53–1
Post-CMR ICD/CRT 0.81 (0.44–1
Quantitative scar (% of total LV myocardium) 1.02 (1.003–
Total scar score (semiquantitative) 1.38 (1.07–1
Chi-square for the multivariable model  15.11, p  0.002. Because of sig
(semiquantitative), only scar percentage was entered into the multivariable mo
CI  conﬁdence interval; other abbreviations as in Table 1.HE-CMR analysis and survival. In the entire study
opulation, approximately one-third of the total
yocardium was scarred on DHE-MR images
mean scar quantified as percentage of total LV
yocardium was 31 21%). Similarly, for the total
opulation, close to 50% of all myocardial segments
assessed semiquantitatively) had transmural or
ear-transmural scar (mean transmurality score was
 5). Similarly, the total scar score (assessed
emiquantitatively) was 2.1 1.1, suggesting a high
roportion of damaged myocardial segments/
e in years
2.5 3.0 3.5 4.0 4.5 5.0
Transmurality score: 1st quartile
Transmurality score: 2nd quartile
Transmurality score: 3rd quartile
Transmurality score: 4th quartile
to 4.0  1st quartile, 4.1 to 9.0  2nd quartile, 9.1 to 12.0  3rd
ciation Among Various Factors and Combined Events
ble Analysis Multivariable Analysis
p Value
Relative Risk
95% CI p Value
0.29
0.03 2.05 (1.18–3.57) 0.01
0.9
0.28
0.28
0.09 0.60 (0.36–1.03) 0.06
0.30
0.32
0.94
0.54
) 0.01 1.02 (1.005–1.03) 0.005
0.01
nt correlation between scar percentage (quantitative) and total scar score  Tim
.0
; 0sso
aria
isk
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.04)
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40atient (approximately 50%). In the transplant
roup (n  5), the mean age was 61  9 years, and
ll were men. The mean LVEF, scar percentage,
nd total scar score were 23  8%, 54  24%, and
.3  0.7, respectively. There was no perioperative
ortality, and all patients in this group survived
uring follow-up.
Subsequently, we compared the scar burden in 2
roups. As shown in Table 2, the mean quantitative
car percentage and semiquantitative scores (trans-
urality score and total scar score) were signifi-
antly higher in those with events versus those
ithout. Kaplan-Meier survival curves on the basis
f quartiles of quantitative scar percentage, trans-
urality score, and total scar score are shown in
igures 2A to 2C. Finally, to account for multiple
onfounding factors impacting outcomes, we per-
ormed univariable and multivariable Cox propor-
ional hazards analysis (Table 3). Receiver-operator
haracteristic curve analysis testing the association
etween quantitative scar percentage and events was
ignificant (area under the curve 0.62, p  0.003).
ecause of a significant association between quan-
itative and semiquantitative measures of scar bur-
en, only 1 such measure (quantified scar percent-
ge) was entered into the multivariable model. To
ccount for the potential impact of revascularization
especially within 6 months of CMR) on outcomes,
e also performed univariable Cox proportional
azards analysis in a subgroup of patients that did
ot have revascularization within 6 months of
MR (n 292, mean age 65 11 years, 219 men,
ean LVEF 24  8%). In this subgroup, the
elative risk of quantitative scar percentage and total
car score was 1.01 (95% CI: 1.00 to 1.02, p 0.04)
nd 1.30 (95% CI: 1.0 to 1.69, p 0.04), respectively.
I S C U S S I O N
o the best of our knowledge, the current study is
he largest to evaluate the ability of semiquantitative
nd quantitative infarct sizing by DHE-CMR to
redict outcomes in high-risk patients with severe
CM. The study population had a high frequency of
isk factors and a high degree of scarred myocar-
ium on DHE-CMR, in the setting of significantly
educed LVEF. For outcomes, we included a com-
osite end point of all-cause mortality and CTx.
e included CTx as a hard end point, because
hose patients were deemed to be in end-stage heart
ailure and would have otherwise died without a
Tx. The mortality rate of our population was
ignificantly high (15% over a mean follow-up of
.6 years). Our study demonstrates that the degree tf myocardial scar, assessed either semiquantita-
ively or quantitatively by DHE-CMR, is a strong
redictor of the composite end point, independent
f other risk factors, and LVEF, even in a high-risk
roup of patients with ICM and severe LV systolic
ysfunction. Incidentally, we also demonstrate that,
imilar to previous suggestions, female gender was
ssociated with worse survival in the study popula-
ion (21,22). We confirmed the baseline similarity
f the 2 groups by calculating propensity scores.
A recent study has also demonstrated the supe-
iority of infarct size, with DHE-CMR, over
VEF and volumes in predicting outcomes in
atients after a previous MI (12); however, the
ean LVEF (43%) was substantially higher, and
he mean LV volumes were substantially smaller, in
ontrast to the current study. Furthermore, the
xtent of myocardial scarring (transmurality score as
ell as total scar score) was substantially lower. The
ortality rate was also substantially lower, likely
eflecting a lesser-risk population. The current
tudy addresses the incremental value of DHE-
MR in a population that is conceivably at a much
igher risk (on the basis of much lower LVEF and
igher scar burden), thus extending the spectrum of
tility to such high-risk patients.
The characteristics of the current study popula-
ion were also unique, likely representing the varied
eferral pattern of our large tertiary care center. The
aseline medication data presented in Table 1,
hich appears suboptimal by modern standards,
epresents the therapy at the time of initial presen-
ation to our institution. The vast majority of such
everely compromised patients get referred to our
ertiary care center for high-risk procedures, from
utside our primary referral area, as demonstrated
n a recent study from our institution (23). This
aseline suboptimal therapy likely reflects the reality
f medical therapy trends in such patients in non-
cademic centers. Indeed, multiple observational
tudies, from different countries, have demonstrated
ess-than-optimal medical therapy during follow-up
fter revascularization procedures (24,25).
In the current population, revascularization in
he follow-up period did not provide any survival
enefit. Although there could be many potential
easons, a likely reason for the lack of benefit could
e that this is already a very high-risk population
because of significantly reduced LVEF and a very
igh scar burden), and the risks of revascularization
otentially outweigh the benefits. However, this is
peculative and needs further prospective confirma-
ion. Also, in the current study, there was relatively
l
t
m
p
t
o
c
(
1
v
H
t
w
r
M
u
r
t
s
(
i
m
a
t
u
c
e
p
a
i
v
p
s
n
p
c
t
r
i
s
b
c
r
t
d
r
n
s
a
D
i
D
p
t
t
e
c
l
C
t
b
c
L
H
s
i
d
v
d
c
m
i
r
p
r
u
g
r
i
m
r
fi
m
h
p
c
r
i
t
c
m
s
p
h
m
t
t
s
u
p
t
a
m
J A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . 2 , N O . 1 , 2 0 0 9
J A N U A R Y 2 0 0 9 : 3 4 – 4 4
Kwon et al.
CMR in Ischemic Cardiomyopathy
41ittle difference in the effectiveness of ICD/CRT
herapy between the 2 groups. There could be
ultiple reasons for that, including differences in
atient populations between our study and some of
he seminal trials of device therapy. Upon comparing
ur population with that of the MADIT-II (Multi-
enter Automatic Defibrillator Implantation Trial-II)
26), the mortality rate in the ICD group was similar:
6% over a 27-month follow-up in the MADIT-II
ersus 14% over 2.6 years’ follow-up in our study.
owever, in the nondevice group for the MADIT-II,
he mortality rate was substantially higher compared
ith our nondevice group (39% vs. 17%). A potential
eason, although purely speculative, could be that the
ADIT-II, unlike our study, excluded patients that
nderwent revascularization in close proximity to en-
ollment. Similar to our study, the MIRACLE (Mul-
icenter InSync Randomized Clinical Evaluation)
tudy of CRT in patients with advanced heart failure
27) only demonstrated a difference in exercise capac-
ty and quality of life, without a difference in overall
ortality between patients with and without CRT. In
further analysis of the same study (28), even symp-
omatic improvements with CRT were less conspic-
ous in patients with ICM as opposed to nonischemic
ardiomyopathy.
Previous studies have demonstrated that both the
xtent of MI and depressed LVEF are important
redictors of survival (3,29,30). Although LVEF is
strong prognostic tool and has been shown to be
nversely related to infarct size (31,32), LVEF and
olumes are subject to preload, afterload, myopathic
rocesses, and the extent of MI. Therefore, infarct
ize might be a more objective and superior prog-
ostic indicator. Previous studies, with myocardial
erfusion scintigraphy, have demonstrated the in-
remental prognostic value of infarct sizing over
raditional LV volume-based variables (33,34).
DHE-CMR has emerged as an extremely accu-
ate clinical tool in assessment of myocardial viabil-
ty, with a demonstrated utility in an ischemic
etting (9,35). Infarct sizing with DHE-CMR has
een shown to correlate with LVEF and other
linical findings in acute infarcts (36) and is highly
eproducible (8,37). Due to a higher spatial resolu-
ion, DHE-CMR has a greater ability for precise
elineation of subendocardial infarctions (38). A
ecent study demonstrated that clinically unrecog-
ized infarcts, identified by DHE-CMR, were the
trongest predictors of major adverse cardiac events
nd mortality (39). In fact, infarct scar quantified by
HE-CMR was shown to be a better marker ofnducible ventricular tachycardia than LVEF (3). uHE-CMR has the ability to not only detect the
resence of irreversible myocardial damage but also
o delineate transmurality of myocardial scar and
he remaining viable myocardium. The transmural
xtent seen on DHE-CMR has been negatively
orrelated to the functional outcome after revascu-
arization (10,40).
linical implications. Several trials demonstrated
hat patients with ICM and systolic dysfunction
enefit from various therapies (medications, revas-
ularization, or device therapy) due to restoration of
V size, shape, and ejection fraction (41–43).
owever, despite such advances, the mortality in
uch patients remains relatively high, and in some
nstances (particularly in patients with severe LV
ysfunction and severe CAD), the benefits of re-
ascularization might be outweighed by the pre-
icted periprocedural risks. Furthermore, with in-
reasing use of CRT, it is being recognized that
ore than one-quarter have a progressive worsen-
ng of their heart failure despite therapy (44). In
ecent years, DHE-CMR has been used to help
redict potential success for CRT (45–48). In a
ecent analysis of the MUSTIC (Multi-site Stim-
lation in Cardiomyopathy) trial, there were sug-
estions that patients with previous MI fail to
espond to CRT, compared with patients with
diopathic dilated cardiomyopathy (49). Further-
ore, Bello et al. (50) demonstrated an inverse
elationship between absolute scar burden, quanti-
ed by DHE-CMR, and functional recovery at 6
onths in response to beta-blocker therapy in 45
eart failure patients. In this study, scar burden also
redicted recovery of systolic function after revas-
ularization. Therefore, extent of myocardial scar-
ing might be an important determinant of mortal-
ty and response to various therapies. It is intuitive
o think that risk stratification in patients with
ongestive heart failure can effectively guide treat-
ent strategies in a cost-effective manner. Our
tudy demonstrates how scar burden is an important
rognostic marker and might identify patients at
igher risk for death. The STICH (Surgical Treat-
ent for Ischemic Congestive Heart failure) trial is
esting whether contemporary medical and device
herapy is equivalent to surgical revascularization. A
ubstudy will examine whether viability provides
seful risk stratification. However, an important
oint that needs to be taken into consideration is
hat, although assessment of myocardial viability
nd scarring are important, the full picture of
yocardium at risk is provided by additional eval-ation of ischemia. Hence, future prognostic stud-
i
p
l
S
s
t
t
u
I
n
s
h
d
L
a
p
m
C
H
c
i
A
f
u
t
s
T
r
s
w
m
o
p
e
l
d
e
i
s
a
a
g
t
H
s
i
t
C
I
f
o
o
d
o
d
s
A
T
a
w
t
f
R
D
C
R
J A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . 2 , N O . 1 , 2 0 0 9
J A N U A R Y 2 0 0 9 : 3 4 – 4 4
Kwon et al.
CMR in Ischemic Cardiomyopathy
42es assessing the incremental value of stress-
erfusion CMR in combination with DHE-CMR
ikely need to be conducted.
tudy limitations. Because this is an observational
tudy conducted at a large tertiary referral center,
here is a distinct possibility of a selection bias. Only
he patients with no contraindications to CMR
nderwent the examination. In the era of CRT and
CDs, a sizable proportion of patients would have
ot have qualified for a CMR study, thus leading to
election bias. A likely reason that these patients
ad not yet received ICD/CRT, despite such re-
uced LVEF, could be the anticipation that their
VEF would improve after revascularization. Not
ll patients had ICD/CRT implantation in the
ost-CMR period, especially because approxi-
ately 30% of patients revascularized in the post-
MR period had an improvement in EF 35%.
owever, there is a possibility that some patients
ould have had such devices implanted at their local
nstitutions, thus potentially altering their survival.
lso, reliance upon the Social Security Death Index
or determination of death status might result in an
nderestimation of clinical outcomes due to the lag
ime in reporting. The difference in the amount of
car between the 2 groups in our study was modest.
his is likely because we are attempting to further
isk-stratify patients (on the basis of the amount of
car) that already have severely depressed LVEF,
hich is in itself is a very powerful prognostic
arker. The baseline medication regimen was sub-
ptimal, by today’s standards, as discussed in the
receding text. Also, at baseline, there was a differ-
nce between groups in use of medical therapy,Radionuclide techniques for the assess- 1990;82:II117–34.ikely due to the inability to use some medications
ue to advanced heart failure. However, this differ-
nce should not have made a significant difference
n our conclusions, because scar burden was a
tronger predictor of death on multivariate survival
nalysis. Also, the overall propensity scores (gener-
ted out of baseline characteristics) were similar in 2
roups. Finally, we did not collect data on diuretic
herapy (other than spironolactone) for this study.
owever, to the best of our knowledge, other than
maller substudies (51), there are no major random-
zed clinical trials demonstrating mortality associa-
ion with diuretics.
O N C L U S I O N S
n patients with ICM and reduced LV systolic dys-
unction, higher LV myocardial scar burden detected
n DHE-CMR is associated with significantly worse
utcomes, including death or need for CTx, indepen-
ent of other risk factors, including revascularization
r device therapies. Delayed hyperenhancement car-
iac magnetic resonance could aid further risk-
tratification of this high-risk population.
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